177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 37390021.
- Also identified by DOI 10.1097/RLU.0000000000004717.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bone is the most common metastatic site in patients with prostate cancer. 177Lu-DOTA-ibandronic acid (177Lu-DOTA-IBA) is a new therapeutic radiopharmaceutical targeting bone metastasis. We report a case of refractory bone pain due to bone metastasis, who demonstrated an excellent therapy response after 3 cycles of 177Lu-DOTA-IBA therapy. In addition, the patient did not have any observable adverse reactions. 177Lu-DOTA-IBA may be a promising radiopharmaceutical for the treatment of bone metastasis.
Medical subject headings
- Bone Neoplasms
- Prostatic Neoplasms